Mustafa Erkan Sari1, İbrahim Yalcin2, Hanifi Sahin2, Mehmet Mutlu Meydanli2, Tayfun Gungor2. 1. Department of Gynecologic Oncology, Zekai Tahir Burak Women's Health Training and Research Hospital, Faculty of Medicine, University of Health Sciences, Ankara, Turkey. drerkansari@gmail.com. 2. Department of Gynecologic Oncology, Zekai Tahir Burak Women's Health Training and Research Hospital, Faculty of Medicine, University of Health Sciences, Ankara, Turkey.
Abstract
OBJECTIVE: The purpose of this study was to determine the risk factors for paraaortic lymph node (LN) metastasis in endometrial cancer (EC) patients who underwent comprehensive surgical staging. METHODS: A total of 641 women with EC (endometrioid, non-endometrioid, or mixed histology) who underwent comprehensive surgical staging including pelvic and paraaortic LN dissection between 2008 and 2016 were included in this retrospective study. Patient data were analyzed with respect to paraaortic LN involvement, and predictive factors for paraaortic LN metastasis were investigated. RESULTS: Lymph node metastasis was detected in 90 (14%) patients, isolated pelvic LN metastasis in 28 (4.3%), isolated paraaortic LN metastasis in 15 (2.3%), and both pelvic and paraaortic LN metastasis in 47 (7.3%) women, respectively. Univariate analysis showed that the risk of paraaortic LN metastasis significantly increased in patients with non-endometrioid histology, age greater than 60 years, grade 3 tumor, deep myometrial invasion, lymphovascular space invasion (LVSI), primary tumor diameter (≥2 cm), cervical stromal invasion, adnexal involvement, serosal invasion, pelvic LN involvement, two or more positive pelvic LNs, and positive peritoneal cytology (p < 0.05). At the end of multivariate analysis, the presence of LVSI [odds ratio (OR), 4.8; 95% confidence interval (CI), 1.25-18.2; p = 0.022] and pelvic LN metastasis (OR, 18.8; 95% CI, 5.7-61.6; p < 0.001) remained as independent risk factors for paraaortic LN involvement in women with EC. CONCLUSION: The presence of LVSI and pelvic LN involvement appear to be independent risk factors for paraaortic LN metastasis in patients with EC. LVSI may be considered as a routine pathological parameter during frozen section analysis in women with EC undergoing surgery.
OBJECTIVE: The purpose of this study was to determine the risk factors for paraaortic lymph node (LN) metastasis in endometrial cancer (EC) patients who underwent comprehensive surgical staging. METHODS: A total of 641 women with EC (endometrioid, non-endometrioid, or mixed histology) who underwent comprehensive surgical staging including pelvic and paraaortic LN dissection between 2008 and 2016 were included in this retrospective study. Patient data were analyzed with respect to paraaortic LN involvement, and predictive factors for paraaortic LN metastasis were investigated. RESULTS: Lymph node metastasis was detected in 90 (14%) patients, isolated pelvic LN metastasis in 28 (4.3%), isolated paraaortic LN metastasis in 15 (2.3%), and both pelvic and paraaortic LN metastasis in 47 (7.3%) women, respectively. Univariate analysis showed that the risk of paraaortic LN metastasis significantly increased in patients with non-endometrioid histology, age greater than 60 years, grade 3 tumor, deep myometrial invasion, lymphovascular space invasion (LVSI), primary tumor diameter (≥2 cm), cervical stromal invasion, adnexal involvement, serosal invasion, pelvic LN involvement, two or more positive pelvic LNs, and positive peritoneal cytology (p < 0.05). At the end of multivariate analysis, the presence of LVSI [odds ratio (OR), 4.8; 95% confidence interval (CI), 1.25-18.2; p = 0.022] and pelvic LN metastasis (OR, 18.8; 95% CI, 5.7-61.6; p < 0.001) remained as independent risk factors for paraaortic LN involvement in women with EC. CONCLUSION: The presence of LVSI and pelvic LN involvement appear to be independent risk factors for paraaortic LN metastasis in patients with EC. LVSI may be considered as a routine pathological parameter during frozen section analysis in women with EC undergoing surgery.
Authors: Kim A H Nicolaije; Nicole P M Ezendam; M Caroline Vos; Dorry Boll; Johanna M A Pijnenborg; Roy F P M Kruitwagen; Marnix L M Lybeert; Lonneke V van de Poll-Franse Journal: Gynecol Oncol Date: 2013-02-19 Impact factor: 5.482
Authors: Ricardo dos Reis; Jennifer K Burzawa; Audrey T Tsunoda; Masayoshi Hosaka; Michael Frumovitz; Shannon N Westin; Mark F Munsell; Pedro T Ramirez Journal: Int J Gynecol Cancer Date: 2015-09 Impact factor: 3.437
Authors: Andrea Mariani; Gary L Keeney; Giacomo Aletti; Maurice J Webb; Michael G Haddock; Karl C Podratz Journal: Gynecol Oncol Date: 2004-03 Impact factor: 5.482
Authors: Daniela de Freitas; Fernando Nalesso Aguiar; Cristina Anton; Carlos Eduardo Bacchi; Jesus Paula Carvalho; Filomena Marino Carvalho Journal: PLoS One Date: 2018-12-17 Impact factor: 3.240
Authors: Sang Il Kim; Joo Hee Yoon; Sung Jong Lee; Min Jong Song; Jin Hwi Kim; Hae Nam Lee; Gyul Jung; Ji Geun Yoo Journal: Int J Med Sci Date: 2021-06-01 Impact factor: 3.738